新型冠状病毒肺炎感染合并心房颤动患者的综合管理认识和建议  

Understanding and recommendations on comprehensive management of patients with COVID-19 infection and atrial fibrillation

作　　者：廖欢燕 韩宇臣 程思源 巫少荣[1] 姚焰[2] 李自成[1] 陈小明[1] 郭军[1] LIAO Huan-yan;HAN Yu-chen;CHENG Si-yuan;WU Shao-rong;YAO Yan;LI Zi-cheng;CHEN Xiao-ming;GUO Jun(Department of Cardiology,The First Affiliated Hospital of Jinan University,Guangzhou Guangzhou 510630,China;Cardiac Arrhythmia Center,Fuwai Hospital,Chinese Academy of Medical Sciences College,Beijing 100037,China)

机构地区：[1]暨南大学附属第一医院心内科,广东省广州市510630 [2]中国医学科学院阜外心血管病医院心律失常中心

出　　处：《中国心血管病研究》2024年第5期385-391,共7页Chinese Journal of Cardiovascular Research

基　　金：中央高校基本科研业务费项目(21623104);广州市科技计划项目(重点研发)(202103000010);暨南大学附属第一医院临床前沿新技术立项项目(JNU1AF-CFTP-2022-a01218)。

摘　　要：研究表明,新型冠状病毒肺炎会导致心房颤动的发生率增加,并且心房颤动同时也是新型冠状病毒肺炎患者病死率增加的主要心血管危险因素。目前,针对新型冠状病毒合并心房颤动患者并未有适当的综合管理策略,鉴于此,在结合国内外的研究成果并参考国内外相关的指南的基础上,本文撰写了关于新型冠状病毒合并心房颤动患者的综合管理的认识和建议,以便进一步规范相关患者的临床管理。Studies have shown that,the corona virus disease 2019(COVID-19)will lead to an increase in the incidence of atrial fibrillation,and atrial fibrillation is also responsible for the mortality rate of patients with COVID-19.Increased major cardiovascular risk factors.Finally,recent studies have found that some adenoviral vector vaccines may cause complications such as venous thrombosis.In view of this,on the basis of combining domestic and foreign research results and referring to relevant domestic and foreign guidelines,this understanding and recommendations are written to further standardize the clinical management of relevant patients.

关 键 词：新型冠状病毒肺炎 心房颤动 机制研究 抗凝 

分 类 号：R541.7[医药卫生—心血管疾病]